REGN
Regeneron Pharmaceuticals, Inc. REGN
$614.98
▲ +0.11% 24H
4.74303.33601.93900.521.2k2001-072007-102014-012020-032026-06

About

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye disor

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees15,343
TickerREGN

Statistics

Market Cap$64.58B
Revenue (TTM)$14.34B
Net Income$4.50B
Net Margin31.4%
EPS$41.48
P/E14.93
P/S4.30
P/B1.98
EV/EBITDA12.81
ROE14.5%
Dividend Yield0.61%
Price$614.98

Data: Twelve Data · Revenue = mcap / P/S

Regeneron Pharmaceuticals, Inc. (REGN) — Market Cap, Revenue, Net Income, P/E | companiesbycap